LOGIN  |  REGISTER
Terns Pharmaceuticals
Assertio

Sarissa Capital Reminds Amarin Shareholders Today Is the Last Day to Vote “FOR” Change

February 21, 2023 | Last Trade: US$0.47 0.04 -7.00

GREENWICH, Conn. / Feb 21, 2023 / Business Wire / Sarissa Capital Management LP (“Sarissa”) today issued the following statement regarding Amarin Corporation plc (NASDAQ: AMRN):

Sarissa urges Amarin shareholders to vote “FOR” change TODAY to remake the Amarin board for shareholders at our upcoming meeting. Given the voting logistics for the meeting, votes must be submitted TODAY in order to be received in time to be counted for tomorrow’s formal deadline.

IF YOU ALREADY VOTED “FOR” ALL PROPOSALS AND SUBMITTED YOUR PROXY CARD, THERE IS NOTHING ELSE YOU NEED TO DO TO SUPPORT SARISSA’S NOMINEES. YOU DO NOT NEED TO VOTE AGAIN.

Shareholders have seen tremendous value destruction at the hands of current Amarin leadership with its operational blunders and poor capital allocation decisions. The board, led by Chairman Per Wold-Olsen, takes no accountability and pays only lip service to its shareholders. Instead, in its attempt to further entrench itself, Amarin’s board has wasted significant amounts of precious shareholders capital to keep shareholder representatives off the board.

Sarissa is Amarin’s largest shareholder. Unlike the current board, we have meaningful “skin in the game” and are fully aligned with shareholders and incentivized to create value at Amarin. In addition, our slate includes Sarissa candidates that helped turn around The Medicines Company until its ultimate sale for nearly $10 billion. We have the qualifications and the experience to help guide Amarin through this critical period.

We urge all shareholders to vote “FOR” the Sarissa Nominees and “FOR” the removal of Chairman Per Wold-Olsen by midnight (New York Time) tonight.

You can vote on the blue proxy card or the white proxy card but if you want to fully support Sarissa, you must make sure that all “FOR” boxes are marked on your proxy card (blue or white) before you submit it.

If you have any questions on how to vote, we recommend that you contact Sarissa’s proxy solicitor, D.F. King, by calling (800) 331-7024 or emailing This email address is being protected from spambots. You need JavaScript enabled to view it..

Visit our website at www.freeamarin.com for helpful information about Sarissa and the need for change at Amarin.

The General Meeting of Amarin shareholders is scheduled for February 28, 2023, BUT TO MAKE SURE YOUR VOTE COUNTS, SUBMIT YOUR VOTE BY MIDNIGHT (NEW YORK TIME) TONIGHT.

Additional Information

Sarissa Capital Management LP (“Sarissa Capital”), together with other participants, filed a definitive proxy statement and an accompanying blue proxy card with the SEC on January 31, 2023, in connection with the solicitation of shareholders of Amarin Corporation plc (the “Company”) at the general meeting of the Company for the election of Sarissa Capital’s slate of highly-qualified nominees (the “General Meeting”). Shareholders are advised to read the definitive proxy statement and other relevant documents related to the General Meeting as they contain important information.

The definitive proxy statement and other relevant documents are available at no charge on the SEC’s website at www.sec.gov and at www.freeamarin.com. The definitive proxy statement and other relevant documents are also available at no charge by directing a request to Sarissa Capital’s proxy solicitor, D.F. King & Co., Inc., 48 Wall Street, New York, New York 10005 (Shareholders can call toll-free: (800) 331-7024).

Astria Therapeutics

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB